Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$14.98 – $27.50
26% from low
Exchange
OTC Link
ADRC
P/S (TTM)
0.0
EV / FCF (TTM)
—
DAIICHI SANKYO S/ADR
No one on the platform currently holds DSNKY.
No tracked institution reports a position in DSNKY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2023-09-28 | $0.1383 | 2023-12-15 |
| Execution date | Ratio |
|---|---|
| 2020-10-09 | 3-for-1 |
No one on the platform has traded DSNKY yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.3% | 14.4% | 10.6% | — | — | — |
| Rev. Growth % | 19.3% | 18.5% | ||||
| Profit Margin % | 12.2% | 11.1% | 9.8% | |||
| Free Cash Flow Margin % | -2.4% | 6.0% | 7.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +84.8% on the P/E track.
At today's price, your expected annual return is +84.9% on the P/E track.
At today's price, your expected annual return is +85.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $2.40T | +10.5% | $150.74 | $146.03–$157.02 | 0.1× | 2 |
| 2028 | $2.44T | +1.6% | $193.08 | $178.10–$208.06 | 0.1× | 2 |
| 2029 | $2.68T | +10.2% | $182.48 | $176.58–$193.92 | 0.1× | 1 |
| 2030 | $3.04T | +13.3% | $228.77 | $221.38–$243.11 | 0.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.25 | $0.24 | -5.6% |
| 2026-05-11 | $0.33 | $0.15 | -55.8% |
| 2026-01-30 | $0.25 | $0.30 | +21.1% |
| 2025-10-31 | $0.30 | $0.16 | -46.7% |
| 2025-07-31 | $0.23 | $0.31 | +30.9% |
| 2025-04-25 | $0.14 | $0.32 | +137.8% |
| 2025-01-31 | $0.20 | $0.21 | +4.0% |
| 2024-10-31 | $0.17 |
| $0.21 |
| +26.6% |
| $60.7B |
| — |
| LZAGFLonza Group AG | $661.04 | -1.70% | $46.2B | — |
| LZAGYLonza Group AG | $65.73 | +0.50% | $46.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
$PFE $BMY $DSNKY and $AMGN are all top lung cancer pharma stocks Old Man Tony! C’mon I thought you took big shots… not big 💩 💩 💩 ⚾️ 💥 🚀 Go Yankees & Cubs 🌎 🐻 👮
View on StockTwits ↗$DSNKY very innovative cancer research company, most undervalued Japanese stock?
View on StockTwits ↗
Truist reiterated $NUVB Buy; $12 $DSNKY DSKYF $HCM BAYRY LLY RIGL Here's what Truist said in its note: https://x.com/Quantumup1/status/2039382081814286759?s=20
View on StockTwits ↗
$DSNKY Misleading quote??? Where are they getting this stock price from?
View on StockTwits ↗$DSNKY Enhertu star? $AZN ? Keep adding? Be contrarian? Be lonesome?
View on StockTwits ↗Citizens🏁 $IMMP and said, We are initiating coverage of Immutep Limited with a Market Outperform rating and $6 price target based on a revenue and earnings multiple analysis. $MRK AUTL ALLO ANL $SMMT $DSNKY - AZN BMY $NUVL Here's what else Citizens had to say: https://x.com/Quantumup1/status/2023730370282197356?s=20
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.